Results 1 to 10 of about 21,074 (263)
The molecular mechanisms of incretin resistance in Type 2 Diabetes Mellitus (T2DM) [PDF]
Nutrition & DiabetesIncretin hormones, specifically glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), serve as crucial mediators of postprandial glucose homeostasis by primarily enhancing glucose-stimulated insulin secretion.
Rawayh Muslim Albaghlany +1 more
doaj +2 more sources
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Frontiers in Endocrinology, 2022 The incretin hormone glucagon-like peptide-1 (GLP-1) has received enormous attention during the past three decades as a therapeutic target for the treatment of obesity and type 2 diabetes.
Rc Waldner, Camila E Orsso, Qiming Tan
exaly +3 more sources
The Origin and Understanding of the Incretin Concept [PDF]
Frontiers in Endocrinology, 2018 Gastrointestinal hormones that stimulate insulin secretion at physiological concentrations are incretins. This concept has recently attracted considerable attention in the wake of drugs developed from the gut hormone GLP-1 (glucagon-like peptide-1) for diabetes therapy.
Jens Rehfeld, Rehfeld Jens F
exaly +5 more sources
Models for Incretin Research: From the Intestine to the Whole Body [PDF]
Endocrinology and Metabolism, 2016 Incretin hormones are produced by enteroendocrine cells (EECs) in the intestine in response to ingested nutrient stimuli. The incretin effect is defined as the difference in the insulin secretory response between the oral glucose tolerance test and an ...
Tae Jung Oh
doaj +1 more source
Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes. [PDF]
PLoS ONE, 2013 The incretin effect on insulin secretion was investigated in 8 subjects with type 2 diabetes (T2D) and 8 with normal glucose tolerance (NGT), using 25, 75, and 125 g oral glucose tolerance tests (OGTT) and isoglycemic intravenous glucose infusions (IIGI).
Andrea Mari +5 more
doaj +1 more source
Exposure–Response Analysis of Cardiovascular Outcome Trials With Incretin-Based Therapies
Frontiers in Endocrinology, 2022 Our study aimed to evaluate the exposure–response relationship between incretin-based medications and the risk of major adverse cardiovascular events (MACE) using cardiovascular outcome trials (CVOTs).
Qi Pan, Mingxia Yuan, Lixin Guo
doaj +1 more source
Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes
Journal of Obesity & Metabolic Syndrome, 2021 Type 2 diabetes (T2D) is a multifaceted metabolic disorder associated with distinctive pathophysiological disturbances. One of the pathophysiological risk factors observed in T2D is dysregulation of the incretin hormones, glucose-dependent insulinotropic
Jared Rosenberg +5 more
doaj +1 more source
Diagnostics, 2022 Elevated glucose-dependent insulinotropic peptide (GIP) levels in obesity may predict the metabolic benefits of n-3 PUFA supplementation. This placebo-controlled trial aimed to analyze fasting and postprandial GIP response to 3-month n-3 PUFA ...
Joanna Goralska +9 more
doaj +1 more source
To be or not to be—an incretin or enterogastrone? [PDF]
Gut, 2006 Glucagon-like peptide 1 does not comfortably fulfil the criterion of a gut derived factor responsible for an enhanced meal related insulin response; it appears logical to add the definition of a "physiological incretin hormone".
Horowitz, M., Nauck, M.
openaire +3 more sources
Incretin‐based therapies [PDF]
Journal of Diabetes, 2012 AbstractIncretin‐based therapies have established a foothold in the diabetes armamentarium through the introduction of oral dipeptidyl peptidase‐4 inhibitors and the injectable class, the glucagon‐like peptide‐1 receptor agonists. In 2009, the American Diabetes Association and European Association for the Study of Diabetes authored a revised consensus ...
Stonehouse, Anthony H +2 more
openaire +2 more sources